Evercore ISI analyst Michael DiFiore downgraded Atara Biotherapeutics to In Line from Outperform without a price target after the company announced that their phase 2 EMBOLD trial of ATA-188 in non-active progressive MS failed to meet its primary endpoint. While stating that “there are some glowing embers amid the wreckage,” the firm acknowledges it will take time for Atara’s early pipeline to develop and for it to demonstrate a successful worldwide TabCel launch before investor confidence is restored.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ATRA: